Pharmicell Co., Ltd. (KRX:005690)

Market Cap	673.25B +4.9%
Revenue (ttm)	23.94B -3.6%
Net Income	-26.78B
EPS	-613.75
Shares Out	60.00M
PE Ratio	n/a
Forward PE	11.63
Dividend	50.00 (0.45%)
Ex-Dividend Date	Dec 29, 2025

Volume	676,679
Open	10,860
Previous Close	10,860
Day's Range	10,650 - 11,250
52-Week Range	8,140 - 21,150
Beta	0.63
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2026

About Pharmicell

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells autologous drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company’s products under development include Cellgram_LC to treat hepatic insufficiency; Cellgram_ED for treating impot...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1968
• Country: South Korea
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 005690

Financial Performance

In 2013, Pharmicell's revenue was 33.41 billion, an increase of 200.63% compared to the previous year's 11.11 billion. Losses were -25.70 billion, 45.7% more than in 2012.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 28, 2026

Data Sources Report a data error